Versartis Inc. (VSAR) Trading Up 3.5%
Shares of Versartis Inc. (NASDAQ:VSAR) were up 3.5% on Wednesday . The company traded as high as $11.70 and last traded at $11.37, with a volume of 59,077 shares traded. The stock had previously closed at $10.99.
A number of analysts have recently weighed in on VSAR shares. Zacks Investment Research raised shares of Versartis from a “sell” rating to a “hold” rating in a research note on Wednesday, June 29th. Canaccord Genuity reaffirmed a “buy” rating and issued a $28.00 price target on shares of Versartis in a research note on Friday, July 29th. Credit Suisse Group AG reaffirmed a “sell” rating and issued a $9.00 price target on shares of Versartis in a research note on Friday, July 29th. Finally, Morgan Stanley reaffirmed a “hold” rating on shares of Versartis in a research note on Saturday, April 30th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. Versartis presently has an average rating of “Buy” and an average target price of $16.60.
The firm’s market capitalization is $335.88 million. The company’s 50 day moving average is $10.90 and its 200-day moving average is $9.30.
Versartis (NASDAQ:VSAR) last announced its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.03. On average, equities research analysts predict that Versartis Inc. will post ($3.11) EPS for the current year.
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.